Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption

Sorafenib significantly improves survival of FLT3-ITD mutated AML patients when used as a post-allogeneic HSCT maintenance. Importantly, clinical trials reported a low rate of toxicities requiring sorafenib discontinuation. The aim of our analysis was to evaluate the real-world experience in patient...

Full description

Bibliographic Details
Main Authors: Sarah Morin, Federica Giannotti, Anne-Claire Mamez, Amandine Pradier, Stavroula Masouridi-Levrat, Federico Simonetta, Yves Chalandon
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
sorafenib
maintenance
HSCT = hematopoietic stem cell transplant
acute myeloid leukemia
drug toxicity and adverse effect
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1095870/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1095870/full

Similar Items